Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan

Ono, Takashi; Wada, Hitoshi; Ishikawa, Hitoshi; Tamamura, Hiroyasu; Tokumaru, Sunao

doi:10.3390/cancers11070993

Cited by 36 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year rates of overall survival (OS) and local control of patients with stages I and II were 75.4% and 74.0%, respectively, and the corresponding rates of stages III and IV were 36.8% and 53.8%, respectively. Furthermore, grade 3 cardiopulmonary toxicities were observed in only three (1.5%) patients [ 38 ]. Table 1 shows that the incidence of cardiopulmonary toxicities in CCRT for esophageal cancer after PBT was less than that after photon RT [ 39 , 40 , 41 , 42 , 43 ].…”

Section: The Role Of Particle Beam Therapy In Multidisciplinary Treatments In Clinicsmentioning

confidence: 99%

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Matsumoto

Fukumitsu²,

Ishikawa

et al. 2021

JPM

View full text Add to dashboard Cite

In this paper, we discuss the role of particle therapy—a novel radiation therapy (RT) that has shown rapid progress and widespread use in recent years—in multidisciplinary treatment. Three types of particle therapies are currently used for cancer treatment: proton beam therapy (PBT), carbon-ion beam therapy (CIBT), and boron neutron capture therapy (BNCT). PBT and CIBT have been reported to have excellent therapeutic results owing to the physical characteristics of their Bragg peaks. Variable drug therapies, such as chemotherapy, hormone therapy, and immunotherapy, are combined in various treatment strategies, and treatment effects have been improved. BNCT has a high dose concentration for cancer in terms of nuclear reactions with boron. BNCT is a next-generation RT that can achieve cancer cell-selective therapeutic effects, and its effectiveness strongly depends on the selective 10B accumulation in cancer cells by concomitant boron preparation. Therefore, drug delivery research, including nanoparticles, is highly desirable. In this review, we introduce both clinical and basic aspects of particle beam therapy from the perspective of multidisciplinary treatment, which is expected to expand further in the future.

show abstract

Section: The Role Of Particle Beam Therapy In Multidisciplinary Treatments In Clinicsmentioning

confidence: 99%

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Matsumoto

Fukumitsu²,

Ishikawa

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…To our knowledge, the failure of RTOG 94-05 was related to high rates of toxicities in 2D era. A latest study in Japan used proton beam therapy for esophageal cancer and reported lower rates of toxicities in comparison to photon radiotherapy [38] . The biological effective dose (BED) in this study was up to 87.2 Gy (67.2 -96.1 Gy).…”

Section: Discussionmentioning

confidence: 99%

Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review

Xiao¹,

Czito²,

Pang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: To investigate the effects and safety profile of radiation dose escalation utilizing computerized tomography (CT) based radiotherapy techniques (including 3-Dimensional conformal radiotherapy, intensity-modulated radiotherapy and proton therapy) in the definitive treatment of patients with esophageal carcinoma (EC) with definitive concurrent chemoradiotherapy (dCCRT). Methods: All relevant studies utilizing CT-based radiation planning, comparing high-dose (≥ 60 Gy) versus standard-dose (50.4 Gy) radiation for patients with EC were analyzed for this meta-analysis. Results: Eleven studies including 4946 patients met the inclusion criteria, with 96.5% of patients diagnosed with esophageal squamous cell carcinoma (ESCC). The high-dose group demonstrated a significant improvement in local-regional failure (LRF) (OR 2.199, 95% CI 1.487-3.253; P<0.001), two-year local-regional control (LRC) (OR 0.478, 95% CI 0.309-0.740; P=0.001), two-year overall survival (OS) (HR 0.744, 95% CI 0.657-0.843; P<0.001) and five-year OS (HR 0.683, 95% CI 0.561-0.831; P<0.001) rates relative to the standard-dose group. In addition, there was no difference in grade ≥ 3 radiation-related toxicities and treatment-related deaths between the groups. Conclusion: Under the premise of controlling the rate of toxicities, doses of ≥ 60 Gy in CT-based dCCRT of ESCC patients might improve locoregional control and ultimate survival compared to the standard-dose dCCRT. While our review supports a dose-escalation approach in these patients, multiple ongoing randomized trial initial and final reports are awaited to evaluate the effectiveness of this strategy.

show abstract

“…Ono et al reported the results of multicenter retrospective study in Japan with 202 (including 90 inoperable) esophageal cancer patients. 85 The 3-year and 5-year OS was 66.7 and 56.3%, respectively. The 5-year LRC was 64.4%.…”

Section: Biology Of Proton Beam Therapymentioning

confidence: 92%

Untitled

2020

Asian Journal of Oncology

View full text Add to dashboard Cite

Proton beam therapy (PBT), because of its unique physics of no-exit dose deposition in the tissue, is an exciting prospect. The phenomenon of Bragg peak allows protons to deposit their almost entire energy towards the end of the path of the proton and stops any further dose delivery. Braggs peak equips PBT with superior dosimetric advantage over photons or electrons because PBT doesn't traverse the target/body but is stopped sharply at an energy dependent depth in the target/body. It also has no exit dose. Because of no exit dose and normal tissue sparing, PBT is hailed for its potential to bring superior outcomes. Pediatric malignancies is the most common malignancy where PBT have found utmost application. Nowadays, PBT is also being used in the treatment of other malignancies such as carcinoma prostate, carcinoma breast, head and neck malignancies, and gastrointestinal (GI) malignancies. Despite advantages of PBT, there is not only a high cost of setting up of PBT centers but also a lack of definitive phase-III data. Therefore, we review the role of PBT in current day practice of oncology to bring out the nuances that must guide the practice to choose suitable patients for PBT.

show abstract

Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan

Cited by 36 publications

References 34 publications

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review

Untitled

Contact Info

Product

Resources

About